Radiation therapy equipment developer RefleXion Medical has raised $100 million in a round of equity financing.
The round was led by Public Sector Pension Investment Board (PSP Investments), a large Canadian pension management firm that focuses on long-term investments. Some of RefleXion's existing investors also participated in the financing.
RefleXion recently received U.S. Food and Drug Administration clearance for use of its RefleXion X1 system for conventional radiation therapy treatments. The company is also developing X1 to perform what it calls biology-guided radiation therapy (BgRT), in which the linear accelerator directs treatment photons to sites of cancer detected with the system's onboard PET/CT component.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
